Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

Ambrilia Biopharma and Merck & Co. in license negotiation

Fasken
Reading Time 1 minute read Subscribe
Client

Confidential Client

Member of the license negotiation team (clinical phase 1) between Ambrilia Biopharma Inc. and Merck & Co. (reported value: $232,000,000)

    Subscribe

    Receive email updates from our team

    Subscribe